PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ChemImage Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Gateway Analytical and Next Breath Partner to Present Webinar Series Focused on Formulation Development for Inhalable and Nasal Drug Products - Gateway Analytical and Next Breath Partner to Present Webinar Series Focused on Formulation Development for Inhalable and Nasal Drug Products - NextBreath.net / GatewayAnalytical.com
Gateway Analytical and Next Breath Partner to Present Webinar Series Focused on Formulation Development for Inhalable and Nasal Drug Products

 

NewswireToday - /newswire/ - Pittsburgh, PA, United States, 2015/10/07 - Gateway Analytical and Next Breath Partner to Present Webinar Series Focused on Formulation Development for Inhalable and Nasal Drug Products - NextBreath.net / GatewayAnalytical.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gateway Analytical, in partnership with Next Breath, will present an OINDP Webinar Series for Dry Powder Inhalers (DPIs), pressurized Metered Dose Inhalers (MDIs), and Nasal Drug Products. The first in the series, In-Depth Characterizations of OINDPs from R&D to Regulatory Submission, will take place on Wednesday, October 14, 2015.

The first in a series of four webinars, presented jointly by Gateway Analytical and Next Breath, will offer attendees insight into utilization of ingredient specific particle sizing (ISPS) to support formulation development, API and excipient selection establishing qualitative and quantitative sameness (Q&Q) and minimizing risk of clinical trials failures via pre-bioequivalence studies. The webinar will be presented jointly by Dr. Oksana Olkhovyk, Senior Scientist at Gateway Analytical, and Dr. Julie Suman, co-founder and President of Next Breath, LLC.

"Establishing and proving bioequivalence of inhaled combination therapies can be difficult without accurately and precisely measuring the particle size distribution of individual active pharmaceutical ingredients and source determination of any foreign particulate matter," said Dr. Oksana Olkhovyk. "During this webinar, we will discuss the utilization of ingredient specific particle sizing (ISPS) to support formulation development, API and excipient selection."

The presentation will pay special attention to collaborative expert support that both companies can provide to reduce risk of clinical trials, mitigate device failure and drive timelines to get the product to market. The webinar will also highlight specific risk mitigating strategies for CMC-required tests.

"As the FDA continues to issue drug product specific bioequivalence guidances, the role of analytical tests for these dosage forms play a critical role in these applications," said Dr. Julie Suman. "This webinar will illustrate study design and data analysis techniques to maximize a positive bioequivalence outcome."

Anyone involved in guaranteeing the development, quality and safety from R&D to regulatory submission for Nasal Drug Product Development delivery systems is encouraged to attend this webinar presentation. For more information about the webinar or to register online, please visit Gateway Analytical.

About Gateway Analytical
Based in Gibsonia, Pa., Gateway Analytical, LLC (gatewayanalytical.com) is a full service, FDA registered and inspected laboratory with specialized expertise in techniques for chemically specific particle sizing and particulate contamination identification. The lab is cGMP compliant, following 21 CFR parts 210 & 211, 21 CFR part 820, and ICH Q7. Accreditations include ISO 9001:2008, ISO 17025:2005, and ASCLD/LAB-International.

Gateway Analytical is a subsidiary of ChemImage Corporation, a leader in chemical imaging technology and instrumentation.

About Next Breath
Next Breath, LLC (nextbreath.net), a subsidiary of AptarGroup, is a cGMP specialty Contract Research Organization (CRO) with analytical expertise for pharmaceutical, biotechnology, and consumer health product development focused on pulmonary, nasal, topical and ophthalmic delivery systems. Next Breath provides comprehensive solutions to the development processes from proof of concept to commercialization. Next Breath has led successful submissions for pulmonary and nasal drug products and devices in the US and international markets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ChemImage Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Gateway Analytical and Next Breath Partner to Present Webinar Series Focused on Formulation Development for Inhalable and Nasal Drug Products

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tifanie Tiberio - ChemImage.com 
412-241-7335 x269 tiberiot[.]chemimage.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChemImage Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ChemImage Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)